SHANGHAI – Suzhou Ribo Life Science Co. Ltd., a Chinese siRNA drug company established in 2007, has raised $20 million in venture capital financing. The round was led by Legend Capital and joined by GGV Capital and Panlin Capital with the participation of the Kunshan RNAi Institute and Legend Star.